Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy
- 1 March 2010
- journal article
- review article
- Published by Springer Nature in Targeted Oncology
- Vol. 5 (1) , 39-52
Abstract
There is an increasing awareness that anatomical approaches based on measurements of tumor size have significant limitations for assessing therapy response. Functional imaging techniques are increasing being used to monitor response to therapies with novel mechanisms of action, often predicting the success of therapy before conventional measurements have changed. Dynamic contrast-enhanced and diffusion magnetic resonance imaging (MRI) are the most advanced in their evidence base, and in this manuscript we focus on them as response parameters. Technology, data gathering methods, and current limitations for these techniques are addressed. With few exceptions, most studies shows that successful treatment is reflected by increases in tumor water diffusion values visible as increased apparent diffusion coefficient values. Most response assessment studies also show that successful treatment results in decreases in tumor vascularization and microvessel permeability.Keywords
This publication has 101 references indexed in Scilit:
- The parametric response map is an imaging biomarker for early cancer treatment outcomeNature Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Metabolic and Vascular Features of Dynamic Contrast-enhanced Breast Magnetic Resonance Imaging and 15O-Water Positron Emission Tomography Blood Flow in Breast CancerAcademic Radiology, 2008
- Scan‐rescan variability in perfusion assessment of tumors in MRI using both model and data‐derived arterial input functionsJournal of Magnetic Resonance Imaging, 2008
- Breast Tumor Xenografts: Diffusion-weighted MR Imaging to Assess Early Therapy with Novel Apoptosis-Inducing Anti-DR5 AntibodyRadiology, 2008
- Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugsNature Clinical Practice Oncology, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agentsBritish Journal of Cancer, 2007
- Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial resultsMagnetic Resonance Imaging, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007